Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86W42
UPID:
THOC6_HUMAN
Alternative names:
Functional spliceosome-associated protein 35; WD repeat-containing protein 58
Alternative UPACC:
Q86W42; B2RA85; Q8NBR1; Q9BTV9
Background:
THO complex subunit 6 homolog, also known as Functional spliceosome-associated protein 35 and WD repeat-containing protein 58, plays a crucial role in mRNA processing and export. It is part of the TREX complex, essential for mRNA export via the TAP/NFX1 pathway and for the production of infectious Kaposi's sarcoma-associated herpesvirus.
Therapeutic significance:
Linked to Beaulieu-Boycott-Innes syndrome, a neurodevelopmental disorder with delayed development and moderate intellectual disability, understanding THO complex subunit 6 homolog's function could unveil new therapeutic strategies.